BLOOMBERG LAW - The future of...
Gilead’s Covid drug win could clog pipeline for other treatments
BLOOMBERG LAW - The future of Covid-19 treatment research is cloudier after the FDA approved Gilead Sciences Inc.'s remdesivir. The approval solidifies the standard of care for hospitalized virus patients in the U.S. Shortages of remdesivir could slow down the development of other new Covid-19 drug... (10/27/2020)
NEUROSCIENCE NEWS - A metabol...
Bacterial metabolism of dietary soy may lower risk factor for dementia
NEUROSCIENCE NEWS - A metabolite produced following consumption of dietary soy may decrease a key risk factor for dementia--with the help of the right bacteria. According to a discovery by EPI's Akira Sekikaw a , elderly Japanese men and women who produce equol--a metabolite of dietary soy create... (10/26/2020)
INSIDE LIVE CHANGING MEDICINE...
Study shows how HIV and cancer drugs accelerate cellular aging
INSIDE LIVE CHANGING MEDICINE - Why do HIV patients tend to show premature signs of aging: cancer, cognitive diseases, osteoporosis? Is the virus itself is causing aging or the drugs being used to treat the virus? In a new study published in Nature Communications , doctoral student Samantha Sanfo... (10/26/2020)
As part of the Conversations ...
COVID-19 & Health Disparities (video)
As part of the Conversations about COVID-19 seminar series, EPI doctoral candidate Chantele Mitchell Miland , and Pitt's director of health sciences diversity, equity, and inclusion, Mario Browne (BCHS '05), discuss COVID-19 and health disparities.
(10/23/2020)
WASHINGTON POST - The pandemi...
The pandemic is rewriting the rules of science. But at what cost? Burke weighs in
WASHINGTON POST - The pandemic has upended norms of the scientific process, from the way studies are funded through the publication of findings. As a result, modelers, like other scientists, have been scrambling to fund and ramp up their operations. The upshot is a lack of agility that has always h... (10/22/2020)